CRISPR Therapeutics AG
Stock Forecast, Prediction & Price Target
CRISPR Therapeutics AG (CRSP) stock Price Target by analysts
$81
Potential upside: 50.12%
CRISPR Therapeutics AG price prediction
What is CRISPR Therapeutics AG stock analysts` prediction?
CRISPR Therapeutics AG stock forecast: Based on 2 Wall Street analysts` predicted price targets for CRISPR Therapeutics AG in the last 3 months, the avarage price target is $81, with a high forecast of $NaN. The average price target represents a 50.12% change from the last price of $53.95.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
CRISPR Therapeutics AG stock Price Target by analysts
Full breakdown of analysts given CRISPR Therapeutics AG price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jay Olson Oppenheimer | 0% 0/2 | 10 months ago | $95 76.07% upside | $49.51 | StreetInsider | Previous targets (1) |
Rick Bienkowski Leerink Partners | 0% 0/2 | 10 months ago | $67 24.17% upside | $50.36 | StreetInsider | Previous targets (1) |
Joon Lee Truist Financial | 0% 0/1 | about 1 year ago | $100 85.34% upside | $46.55 | TheFly | Previous targets (0) |
Luca Issi RBC Capital | 0% 0/1 | about 1 year ago | $60 11.20% upside | $50.13 | StreetInsider | Previous targets (0) |
Benjamin Burnett Stifel Nicolaus | 0% 0/1 | about 1 year ago | $59 9.35% upside | $50.01 | StreetInsider | Previous targets (0) |
Gil Blum Needham | 0% 0/2 | about 1 year ago | $84 55.68% upside | $50.11 | StreetInsider | Previous targets (1) |
Jack Allen Robert W. Baird | 0% 0/1 | over 1 year ago | $52 -3.62% downside | $53.29 | StreetInsider | Previous targets (0) |
Unknown Citigroup | N/A | almost 3 years ago | $63 16.76% upside | $55.72 | Benzinga | N/A |
Geulah Livshits Chardan Capital | 100% 1/1 | about 3 years ago | $79.3 46.97% upside | $81.39 | Benzinga | Previous targets (0) |
Kostas Biliouris BMO Capital | 0% 0/1 | about 3 years ago | $98 81.63% upside | $70.73 | Benzinga | Previous targets (0) |
Gil Blum Needham | 0% 0/2 | over 3 years ago | $170 215.08% upside | $61.97 | TipRanks Contributor | Previous targets (1) |
Rick Bienkowski Leerink Partners | 0% 0/2 | over 3 years ago | $120 122.41% upside | $60.97 | TipRanks Contributor | Previous targets (1) |
Yanan Zhu Wells Fargo | 0% 0/1 | over 3 years ago | $105 94.61% upside | $67.66 | TipRanks Contributor | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/2 | almost 4 years ago | $172 218.79% upside | $93 | TheFly | Previous targets (1) |
Edward Tenthoff Piper Sandler | 0% 0/1 | almost 4 years ago | $180 233.61% upside | $102.59 | TheFly | Previous targets (0) |
Arlinda Lee Canaccord Genuity | 0% 0/1 | about 4 years ago | $160 196.54% upside | $122.55 | TheFly | Previous targets (0) |
Anthony Butler Roth Capital | 0% 0/1 | over 4 years ago | $171 216.93% upside | $127 | TheFly | Previous targets (0) |
Maury Raycroft Jefferies | 0% 0/1 | over 4 years ago | $172 218.79% upside | $124.93 | MarketWatch | Previous targets (0) |
CRISPR Therapeutics AG Financial Estimates
CRISPR Therapeutics AG Revenue Estimates
CRISPR Therapeutics AG EBITDA Estimates
CRISPR Therapeutics AG Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $913.08M N/A | $436K -99.95% | $371.20M 85038.99% | Avg: $330.73M Low: $43.74M High: $2.05B avg. -10.90% | Avg: $849.65M Low: $88.55M High: $5.24B avg. 156.89% | Avg: $1.20B Low: $125.48M High: $7.43B avg. 41.70% | Avg: $1.81B Low: $189.14M High: $11.20B avg. 50.72% |
Net Income
% change YoY
| $377.66M N/A | $-650.17M -272.15% | $-153.61M 76.37% | Avg: $-393.36M Low: $-690.01M High: $399.27M avg. -156.07% | Avg: $-203.86M Low: $-518.89M High: $678.13M avg. 48.17% | Avg: $-103.15M Low: $-797.27M High: $16.96M avg. 49.40% | Avg: $130.52M Low: $-21.47M High: $1.00B avg. 226.53% |
EBITDA
% change YoY
| $373.52M N/A | $-673.16M -280.21% | $-202.70M 69.88% | Avg: $-130.79M Low: $-814.17M High: $-17.29M avg. 35.47% | Avg: $-336.01M Low: $-2.07B High: $-35.02M avg. -156.89% | Avg: $-476.13M Low: $-2.94B High: $-49.62M avg. -41.70% | Avg: $-717.66M Low: $-4.43B High: $-74.80M avg. -50.72% |
EPS
% change YoY
| $4.97 N/A | -$8.36 -268.20% | -$1.94 76.79% | Avg: -$4.46 Low: -$8.71 High: $5.04 avg. -129.89% | Avg: -$2.3 Low: -$6.55 High: $8.56 avg. 48.53% | Avg: -$1.3 Low: -$10.06 High: $0.21 avg. 43.27% | Avg: $1.65 Low: -$0.27 High: $12.73 avg. 226.53% |
Operating Expenses
% change YoY
| $539.55M N/A | $563.34M 4.40% | $463.49M -17.72% | Avg: $26.32B Low: $3.48B High: $163.87B avg. 5579.92% | Avg: $67.63B Low: $7.04B High: $417.71B avg. 156.89% | Avg: $95.83B Low: $9.98B High: $591.90B avg. 41.70% | Avg: $144.44B Low: $15.05B High: $892.15B avg. 50.72% |
FAQ
What is CRISPR Therapeutics AG stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 42.00% in 2025-2028.
We have gathered data from 19 analysts. Their low estimate is -690.01M, average is -393.36M and high is 399.27M.
What is CRISPR Therapeutics AG stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 59.60% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $43.74M, average is $330.73M and high is $2.05B.
What is CRISPR Therapeutics AG stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 47.11% in 2025-2028.
We have gathered data from 19 analysts. Their low earnings per share estimate is -$8.71, average is -$4.46 and high is $5.04.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering CRISPR Therapeutics AG stock. The most successful analyst is Jay Olson.